HCW Biologics Inc. (NASDAQ: HCWB) adjourned its special meeting of stockholders on April 27, 2026, without conducting business due to insufficient attendance to meet quorum requirements. The biopharmaceutical company moved the proposals to its annual meeting scheduled for June 15, 2026.

The company will continue soliciting votes from stockholders regarding proposals related to warrants issued to Armistice Capital Master Fund Ltd. Armistice invested $17.4 million in HCW Biologics and received warrants to purchase up to 5,497,702 shares of common stock at $0.6055 per share, subject to stockholder approval.

HCW Biologics stated it must seek stockholder approval every 60 days until obtained and will continue incurring costs for additional meetings until approval is secured. The record date for eligible voters was April 22, 2026.

The annual meeting will take place virtually on June 15, 2026, at 10:00 a.m. Eastern Time, where stockholders will consider the warrant proposals along with other annual meeting matters.

HCW Biologics is a clinical-stage company developing fusion immunotherapeutics for diseases involving chronic inflammation, including autoimmune diseases, cancer, and senescence-associated conditions. The company has entered into two licensing agreements for some of its proprietary molecules.